SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Rani Therapeutics Holdings, Inc. (RANI) News

Follow Rani Therapeutics Holdings, Inc. (RANI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol RANI Asset equity Sector Markets 90 days 6 Last 0.8094 Updated Sep 14, 2026, 09:39 PM UTC Open live news feed Open RANI chart & news
L RANI: RaniPill's strong clinical data and major partnerships drive growth, with manufacturing and cash runway secured The company showcased its RaniPill technology for oral biologic delivery, highlighted a major partnership with Chugai, and reported strong clinical data for RT-114. Manufacturing scale-up and a robust cash position suppo NEWS | Sep 14, 2026, 09:39 PM UTC L RANI: Oral biologic delivery platform advances with key partnerships, strong data, and manufacturing scale-up The company showcased its RaniPill platform for oral biologic delivery, highlighted a major Chugai partnership, and reported strong RT-114 clinical data. Manufacturing scale-up and a robust cash position support multiple NEWS | Sep 14, 2026, 08:55 PM UTC L RANI - Rani Therapeutics to Participate in Upcoming September Conferences RANI - Rani Therapeutics to Participate in Upcoming September Conferences EQUITY | Sep 08, 2026, 12:01 PM UTC L RANI - Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update RANI - Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update EARNINGS | Aug 13, 2026, 08:06 PM UTC L Rani Therapeutics Appoints Michelle Gilson Rani Therapeutics appoints new board member EQUITY | Aug 04, 2026, 12:01 PM UTC L RANI Therapeutics announces positive initial phase 1a data for rt-114 for the treatment of obesity, with oral bioavailability exceeding matc RANI Therapeutics announces positive initial phase 1a data for rt-114 for the treatment of obesity, with oral bioavailability exceeding matched subcutaneous dosing Rani Therapeutics - no adverse events attributed to rani EQUITY | Jul 15, 2026, 12:01 PM UTC